We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > vosoritide

News List

BioMarin Expands Vosoritide Clinical Program americanpharmaceuticalreview
November 18, 2020
BioMarin Pharmaceutical announced the Company is expanding its clinical program for vosoritide, an investigational analog of C-type Natriuretic Peptide (CNP), with two new Phase 2 studies.
BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia drugs
June 24, 2019
BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia.
New Experimental Drug, Vosoritide, Combats Leading Cause of Dwarfism drugs
June 24, 2019
New Experimental Drug, Vosoritide, Combats Leading Cause of Dwarfism.